Recent Research from Department of Medical Oncology Highlight Findings in Adenocarcinoma (Trifluridine/tipiracil Plus Oxaliplatin +/- Nivolumab Vs Folfox +/- Nivolumab In Her2 Negative Advanced Oesogastric Adenocarcinoma: the...).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    Immunotherapy Weekly; 9/3/2024, p948-948, 1p
  • Additional Information
    • Abstract:
      A recent report from the Department of Medical Oncology in Marseille, France discusses the use of trifluridine/tipiracil (FTD/TPI) in the treatment of advanced/metastatic gastric and gastroesophageal junction adenocarcinomas (aGA/GEJA). The combination of FTD/TPI with oxaliplatin and nivolumab has shown promising results and a manageable safety profile. The study aims to evaluate the efficacy and safety of FTD/TPI plus oxaliplatin with or without nivolumab compared to the standard of care FOLFOX regimen in patients with HER2 negative aGA/GEJA who are not eligible for triplet chemotherapy. The study is a prospective randomized trial that will include 118 patients. Nivolumab will be used for patients whose tumors express PD-L1 with a CPS score >= 5. This research provides valuable data on the association of FTD/TPI plus oxaliplatin with or without nivolumab in the first-line palliative setting for patients with aGA/GEJA. [Extracted from the article]
    • Abstract:
      Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)